Supplementary Figure 2 from Navitoclax (ABT-263) Reduces Bcl-xL–Mediated Chemoresistance in Ovarian Cancer Models

MLA

Lisa D. Belmont, et al. Supplementary Figure 2 from Navitoclax (ABT-263) Reduces Bcl-XL–Mediated Chemoresistance in Ovarian Cancer Models. Apr. 2023. EBSCOhost, https://doi.org/10.1158/1535-7163.22496800.

APA

Lisa D. Belmont, Wayne J. Fairbrother, Peng Yue, Franklin V. Peale, Jiping Zha, Nguyen Tan, & Maureen Wong. (2023). Supplementary Figure 2 from Navitoclax (ABT-263) Reduces Bcl-xL–Mediated Chemoresistance in Ovarian Cancer Models. https://doi.org/10.1158/1535-7163.22496800

Chicago

Lisa D. Belmont, Wayne J. Fairbrother, Peng Yue, Franklin V. Peale, Jiping Zha, Nguyen Tan, and Maureen Wong. 2023. “Supplementary Figure 2 from Navitoclax (ABT-263) Reduces Bcl-XL–Mediated Chemoresistance in Ovarian Cancer Models,” April. doi:10.1158/1535-7163.22496800.